The deadline for nominations to the Maryland Incubator Company of the Year Award, which I will be helping judge, has been extended to March 31, 2010.
All Maryland Incubator and Incubator affiliate companies are invited to apply.
The website to apply is http://www.mdincubatoraward.com/2010/2010_nominationform.aspx
More information is at http://www.mdincubatoraward.com
Coming soon, a book by frequent BiotechBlog contributor, John Avellanet. In this new book — Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine — John teaches you how to take advantage of evolving FDA compliance requirements and cutting-edge new product development techniques to bring your new medicine to market faster, easier, for less cost and less risk.
Full details on the book are available on Logos Press’ website, and the book is available for pre-order at Barnes and Noble. You can read more about John at his homepage and blog.
Media outlets interested in a review copy can contact email@example.com.
DC Biotech is an informal networking group in the DC area. A discussion forum is hosted on LinkedIn, and regular happy hours are held in the DC area.
I recently gave a talk on educating the next generation of biotechnology managers and founders at a biotechnology education workshop. My sense is that the traditional education paths are not ideal ways to prepare individuals to manage or start biotechnology companies, and I describe cases from Best Practices in Biotechnology Education and courses I have been involved with to illustrate how educational programs can better prepare students for these roles.
I’ve attached a copy of my presentation below.
Drug Patent Expirations in March 2010
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number|| Patent Expiration|
|AZASITE||Inspire||azithromycin||5,192,535||Mar 9, 2010|
|SOLAGE||Stiefel Labs Inc||mequinol; tretinoin||5,470,567||Mar 19, 2010|
|PYLERA||Axcan Scandipharm||bismuth subcitrate potassium; metronidazole; tetracycline||5,476,669||Mar 23, 2010|
|KADIAN||Actavis Elizabeth||morphine sulfate||5,378,474||Mar 23, 2010|
|PYLERA||Axcan Scandipharm||bismuth subcitrate potassium; metronidazole; tetracycline||5,196,205||Mar 23, 2010|
|EMBEDA||Alpharma King||morphine sulfate; naltrexone hydrochloride||5,378,474||Mar 23, 2010|
|CADUET||Pfizer||amlodipine besylate; atorvastatin calcium||4,681,893*PED||Mar 24, 2010|
|LIPITOR||Pfizer||atorvastatin calcium||4,681,893*PED||Mar 24, 2010|
|CARDENE SR||Ekr Therap||nicardipine hydrochloride||5,198,226||Mar 30, 2010|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.Courtesy of DrugPatentWatch.com